CN104975376A - Chiral nanometer fiber and its preparation method and use - Google Patents
Chiral nanometer fiber and its preparation method and use Download PDFInfo
- Publication number
- CN104975376A CN104975376A CN201510321191.6A CN201510321191A CN104975376A CN 104975376 A CN104975376 A CN 104975376A CN 201510321191 A CN201510321191 A CN 201510321191A CN 104975376 A CN104975376 A CN 104975376A
- Authority
- CN
- China
- Prior art keywords
- chirality
- nanofiber
- cancer
- cell
- chiral
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention relates to the field of biological medicines and especially relates to a chiral nanometer fiber and its preparation method and use. The chiral nanometer fiber raw material mainly comprises zinc ions and chiral amino acid. The diameter of the chiral nanometer fiber is in a range of 120-160nm. The chiral nanometer fiber can be used for preparation of drugs for treating and preventing tumor cells. The chiral nanometer fiber can influence extracellular HSP90 functions thereby influencing an extracellular HSP90 related signal path, can well inhibit tumor invasion and migration activity, does not enter into cells, and does not influence cell normal physiological functions. When the chiral nanometer fiber is degraded in vivo, the degraded ingredient zinc ions and aspartic acid have very good biocompatibility and does not damage the body at an appropriate treatment concentration.
Description
Technical field
The present invention relates to biomedicine field, particularly relate to a kind of chirality nanofiber and its preparation method and application.
Background technology
Heat shock protein (Heat Shock Protein, HSP) is a kind of important Function protein in cell, and it take part in the physiology course of various kinds of cell, as the maintenance etc. of cell proliferation, cell cycle; And HSP also can by stoping the sex change of protein and impelling denatured protein renaturation, and the cell under protection stress conditions is from damage.Follow-up research finds, HSP not only take part in the physiological metabolism process of normal tissue cell, and in the development and deteriorating course of tumour, also play crucial effect.HSP90 as the important forming member of HSP protein families and most of tumour correlated characteristic closely bound up, this comprising: the proliferation signal continued, escape growth inhibition, induction of vascular generates, activation Infiltration and metastasis, opposing cell death, copy more than, escape from immune damage and genomic instability; Compared to normal cell, there is in tumour cell higher level and highly active HSP90, therefore, can by the treatment suppressing the biologically active of HSP90 to realize tumour.
At present, the research for HSP90 treatment of cancer mainly concentrates on the inhibitor aspect of development HSP90, by sources HSP90 inhibitor can be divided into natural inhibitor and the large class of artificial inhibitor two.Wherein, geldanamycin (geldanamycin, GA) reach by being separated in streptomyces hygroscopicus, the N of its emulative combination of energy and HSP90 holds ATP/ADP binding domain, and the affinity of it and HSP90 is far better than ATP and ADP, by suppressing the activity of HSP90, thus destroy cells survival, propagation and stress be crucial in process the stability of protein, finally can play antineoplastic action; 17-allylamine-17-demethoxygeldanamycin (17-allylamino-17-demethoxy-geldanamycin, 17-AAG) and 17-dimethylamino-17-demethoxygeldanamycin (17-2-dimethylaminoethylamino-17-demethoxygeldanamycin, 17-DMAG) as two kinds of derivatives of GA, there is the mechanism of action similar with GA; Effective inhibitor that the large lopps antibiotic-radicicol (radicicol, RA) obtained also is HSP90N end is separated from fungi, and, taller than GA and 17-AAG of the affinity of it and HSP90; The derivative that the cyclopropyl radicicol (cyclopropraradicicol) that KF25706 and Ymamoto etc. that consonance fermentation company of Japan researches and develops researches and develops is RA; Be separated from streptomycete fermentation liquid the ovobiocin obtained and by being combined with the ATP/ADP binding site that the C of HSP90 holds, the Dimerized effect of HSP90 can be blocked, suppress HSP90 normal function, the propagation of Tumor suppression; Deriving from the polyphenol catechin of plant, osajin and beta carotene etc. is all HSP90 inhibitor; In addition, purine is the inhibitor PU3 of architecture basics, the complex compound-cis-platinum (CDP) of metal platinum and small peptide derivative Phe-D-Trp-Leu have certain inhibition to HSP90.Although studied the multiple HSP90 inhibitor of discovery and Prof. Du Yucang at present, these inhibitor still also exist weak point.Such as, GA has poorly water-soluble, distribution in vivo without the feature such as specificity, hepatotoxicity wind agitation be stronger; The 17-AAG features such as also existence and stability is poor, solubility is limited, bioavailability is low; The feature of RA also existence and stability difference, lacks antitumor activity in animal model test; Some other inhibitor also also exists the features such as tumor inhibitory effect difference or higher malicious seondary effect.
By finding the further investigation of HSP90 function, HSP90 is except can except promoting in cell that the activity of the folding of protein and stable protein plays a role, it also can be positioned at surface of cell membrane or be secreted in extracellular matrix by playing a role with extracellular protein or active factors, change the signal path of cell, thus play important effect in the invasion and attack and migration of tumour.And can only could secrete HSP90 when being subject to environment-stress compared to normal cell, kinds of tumor cells can the secretion HSP90 of composing type.Therefore, when inhibitor is only for extracellular HSP90 effect, it can not only control the deterioration process of tumour effectively in theory, but also greatly reduces Normocellular toxic and side effect.
Summary of the invention
The object of the present invention is to provide a kind of chirality nanofiber and its preparation method and application, described chirality nanofiber can overcome the deficiency of existing HSP90 inhibitor, plays effect at extracellular environment.
For reaching this object, the present invention by the following technical solutions:
First aspect, the invention provides a kind of chirality nanofiber, and described chirality nanofiber raw material comprises zinc ion and chiral amino acid,
Wherein, the diameter of described chirality nanofiber is 120-160nm.
Zinc ion and amino acid are the necessary element wanted of body weight for humans and constituent, there is good biocompatibility, zinc ion and amino acid combination can form longer nanofibrous structures, cannot permeates cell membranes, avoid material and enter in normal cell to have an impact to HSP90 function and cause toxic and side effect; And zinc ion with HSP90 in conjunction with time, can with the amino acid residue generation coordination of HSP90, assist chirality nanofiber and HSP90 to have an effect.
The diameter of chirality nanofiber is 120-160nm, and be the chirality fiber of 100nm compared to diameter, this fiber has larger surface area can in conjunction with more tumor correlated albumen matter.
As optimal technical scheme, described chiral amino acid is D/L-aspartic acid or D/L-histidine, is preferably D/L-aspartic acid.
The nanofiber of chirality described in the present invention stability retention time is in aqueous more than 24 hours.
Preferably, the diameter of described chirality nanofiber is 120-160nm, such as, can be 120nm, 122nm, 125nm, 130nm, 138nm, 140nm, 145nm, 150nm, 155nm or 160nm, is preferably 130-160nm.
Preferably, the length of described chirality nanofiber is 150-800 μm, can be such as 150 μm, 200 μm, 300 μm, 350 μm, 400 μm, 450 μm, 500 μm, 550 μm, 600 μm, 650 μm, 700 μm, 750 μm or 800 μm, be preferably 200-500 μm.
Preferably, the synthetic method of described chirality nanofiber is self-assembly method.
Second aspect, the invention provides the preparation method of chirality nanofiber as described in relation to the first aspect, comprises the following steps:
(1) chiral amino acid and zinc nitrate solution is prepared;
(2) by zinc nitrate solution titration chiral amino acid solution under the condition stirred, mixture reacts 7-18 days on the interface of water-absolute ethyl alcohol, then with 10mL absolute methanol washing 3-5 time, puts into vacuum drying chamber dry.
The third aspect, the invention provides chirality nanofiber as described in relation to the first aspect for affecting the purposes of extracellular HSP90 associated signal paths.
Preferably, described signal path is NF-kappa B.
Fourth aspect, the invention provides the application of chirality nanofiber in preparation treatment and prevention cancer drug as described in relation to the first aspect.
Preferably, described cancer is any one or at least two kinds of combinations in cancer of the stomach, liver cancer, the carcinoma of the rectum, colon cancer, ED-SCLC, prognosis of squamous cell lung cancer, adenocarcinoma of lung, bronchiolar adenocarcinoma, thyroid cancer, cervical carcinoma, oophoroma, prostate cancer, the cancer of the esophagus, lymphepithelioma, melanoma, breast cancer, duct carcinoma, osteosarcoma, basosquamous cell carcinoma, carcinoma of urinary bladder, neuroblastoma and glioblastoma.
To those skilled in the art, even if do not understand principle of the present invention, can implement equally, reproduce the present invention, namely whether principle of the present invention is cheer and bright, do not affect enforcement of the present invention and reproduction.A kind of chirality nanofiber of the present invention and application thereof, its principle is:
HSP90 can be positioned at surface of cell membrane or be secreted into by playing a role with extracellular protein or active factors in extracellular matrix, changes the signal path of cell, thus plays important effect in the invasion and attack and migration of tumour; Zn-Asp chirality nanofiber of the present invention has longer nanofibrous structures, permeates cell membranes cannot enter cell, and zinc ion on chirality nanofiber can with the amino acid residue generation coordination of HSP90, play a role, affect HSP90 extracellular activity, the NF-kappa B signal path regulated by the outer HSP90 of T suppression cell, the propagation of inhibition tumor cell, invasion and attack and migration, and cell autophagy, and to normal cell, there is lower malicious seondary effect.
Compared with prior art, the present invention has following beneficial effect:
(1) chirality nanofiber of the present invention good stability in aqueous, can keep stable in aqueous and reach more than 24 hours;
(2) chirality nanofiber of the present invention can not enter tumour cell, can play its inhibit feature at tumour cell external environment, and material can be avoided to enter the toxic and side effect caused HSP90 function effect in normal cell;
(3) chirality nanofiber of the present invention can interact with the heat shock protein HSP90 in extracellular environment, and suppress it active to a certain extent, thus affect extracellular HSP90 associated signal paths, as NF-kappa B realizes inhibition to tumour cell, can the better invasion and attack of Tumor suppression and migratory activity;
(4) even if chirality nanofiber degradation in vivo of the present invention, its degraded composition zinc ion and aspartic acid also have extraordinary biocompatibility, can not cause any harm under suitable concentration for the treatment of to body.
Accompanying drawing explanation
Fig. 1 is Zn-Asp chirality nanofiber (a) of the present invention, (b), (c) and (d) are transmission electron microscope figure, and (e) is that circular dichroism absorbs figure.
Fig. 2 is the interaction result of Zn-Asp chirality nanofiber of the present invention and tumor correlated albumen matter, (a) and (b) for Zn-Asp chirality nanofiber with HSP90 in conjunction with situation, (c) is Zn-Asp chirality nanofiber and gelatinase in conjunction with situation.
Fig. 3 be Zn-Asp chirality nanofiber of the present invention on the impact of tumour cell A549 survival rate, (a) condition is 1% serum, and (b) condition is 10% serum.
Fig. 4 is that Zn-Asp chirality nanofiber of the present invention is on the impact of the migration (a) of tumour cell A549 with invasion and attack vigor (b).
Fig. 5 be Zn-Asp chirality nanofiber of the present invention to the molecular mechanism of tumour cell A549 effect of vigor, the protein transcriptional level of (a) related gene, the phosphorylation level of (b) related gene.
Fig. 6 be Zn-Asp chirality nanofiber of the present invention to tumour cell autophagocytosis result figure, the Western Blotting that (a) is autophagy marker protein LC3 schemes, the transmission electron microscope figure that (b) is tumour cell.
Detailed description of the invention
For further setting forth the technological means and effect thereof that the present invention takes, further illustrate technical scheme of the present invention below in conjunction with accompanying drawing by detailed description of the invention, but the present invention is not confined in scope of embodiments.
The preparation of embodiment 1:Zn-Asp chirality nanofiber
(1) preparation of Freamine Ⅲ: the aspartic acid taking 133mg is dissolved in 6mL absolute ethyl alcohol, adds the sodium hydrate aqueous solution of 1mL 2mmol, is mixed with the aspartic acid solution of 1mmol;
(2) preparation of zinc nitrate solution: the zinc nitrate hexahydrate taking 595mg is dissolved in the ultra-pure water of 2mL, is mixed with the zinc nitrate solution of 2mmol;
(3) by zinc nitrate solution titration aspartic acid solution under the condition stirred, mixture reacts 14 days on the interface of water-absolute ethyl alcohol, then with 10mL absolute methanol washing three to five times, puts into vacuum drying chamber drying for standby.
As can be seen from Figure 1, Zn-Asp chirality nanofiber is in threadiness, and diameter is at about 150nm, and length can reach 200-500 μm.
The interaction of embodiment 2:Zn-Asp chirality nanofiber and tumor correlated albumen matter
1, Zn-Asp chirality nanofiber and HSP90 interact
200 μ g Zn-Asp chirality nanofibers contain 2,4,8,16,24,32,48 and 72 μ g purifying respectively recombinant protein HSP90 with 1mL hatches 1 hour at 37 DEG C, centrifugally abandon supernatant, after PBS buffer solution 3 times, final sediment is resuspended with 2 × sample-loading buffer, then SDS-PAGE electrophoresis is run, coomassie brilliant blue staining.
2, Zn-Asp chirality nanofiber and tumour cell interact
(1) by tumor cell inoculation in the DMEM culture medium of serum-free, cultivate after 48 hours, get supernatant and be labeled as sample SF;
(2) by tumor cell inoculation in the DMEM culture medium of serum-free, cultivate after 24 hours, in culture medium, add 200 μ g/mL Zn-Asp chirality nanofibers cultivate 24 hours again, get supernatant and be labeled as sample SF+D (S) and SF+L (S);
(3) by tumor cell inoculation the DMEM culture medium of serum-free or containing 10% serum DMEM in, cultivate after 24 hours, the D-/L-Zn-Asp chirality nanofiber respectively getting supernatant respectively with the 200 μ g of 1mL hatches 1 hour, sample after hatching is centrifugal abandons supernatant, by precipitation with PBS buffer solution once, more resuspended and be labeled as sample SF+D (F), SF+L (F), 10%FM+D (F) and 10%FM+L (F) with 2 Χ sample-loading buffers;
(4) above-mentioned sample is run SDS-PAGE electrophoresis according to the method for gelatin zymogram, rinsing, hatches, coomassie brilliant blue staining.
Fig. 2 can find out, (a) shows that 200 μ g/mL D-/L-Zn-Asp chirality nanofibers cause the suppression of the cell viability of 61% and 44% respectively; B () shows that 200 μ g/mL D-/L-Zn-Asp chirality nanofibers cause the suppression of the cell viability of 35%; Can obtain, under 1% serum condition, D-/L-Zn-Asp chirality nanofiber has larger inhibition to cell survival.
Embodiment 3:Zn-Asp chirality nanofiber is to the suppression of tumor cell proliferation, migration and invasion
Zn-Asp chirality nanofiber 200 μ g/mL is joined in 1%FBS cell culture medium and 10%FBS cell culture medium respectively, incubated cell 24 hours, and the parallel control group not adding chirality nanofiber in cell culture medium is set, then detect the change of cell viability, migration and invasion.
As can be seen from Figure 3, (a) and (b) shows that D-/L-Zn-Asp chirality nanofiber in conjunction with HSP90, and can show obvious concentration dependant effect; C () D-/L-Zn-Asp chirality nanofiber also can in conjunction with different gelatinases: the activity form of MMP-9 polymer, proMMP-9, MMP-2 precursor and MMP-2.
Fig. 4 can find out, (a) shows that the D-/L-Zn-Asp chirality nanofiber of 200 μ g/mL causes the suppression of the cell migration of 54%; B () shows that the D-/L-Zn-Asp chirality nanofiber of 200 μ g/mL causes the suppression of the cell invasion of 78% and 74% respectively.
Embodiment 4:Zn-Asp chirality nanofiber is on the impact of tumour associated signal paths
1, gene expression dose aspect
200 μ g/mL D/L-(Zn-Asp) chirality nanofibers are joined 10%FBS cell culture medium incubated cell 24 hours, and the parallel control group not adding chirality nanofiber in cell culture medium is set.Cell Trizol extracting method after process obtains the total serum IgE of each cell sample, corresponding cDNA is synthesized with the Reverse Transcriptase kit of Roche Holding Ag, the cDNA getting equivalent carries out Real-Time PCR, analyzes the expression of gene I κ B α, p50, p52 and p65 important in NF-kB approach.
As can be seen from Fig. 5 (a), the gene expression dose of I κ B α, p50, p52 and p65 is all lowered, I κ B alpha expression level is lowered to 0.3-0.6 from 1.0, p50 expression is lowered to 0.6-0.8 from 1.0, p52 expression is lowered to 0.5-0.9 from 1.0, p65 expression is lowered to 0.8-0.9 from 1.0, and D-(Zn-Asp) chirality nanofiber is larger on the impact of gene deregulation level.
2, protein expression aspect
200 μ g/mL D/L-(Zn-Asp) chirality nanofibers are joined 10%FBS cell culture medium incubated cell 24 hours, and the parallel control group not adding chirality nanofiber in cell culture medium is set.After process, discard culture medium, the PBS buffer solution of cell precooling is washed twice, then add appropriate RIPA cell pyrolysis liquid and carry out lysis.Carry out quantitatively by BCA method to each product of cell lysis, respectively get the protein of 25 μ g, add 2 × sample-loading buffer, run SDS-PAGE electrophoresis, then carry out western blot detection, detect the antibody (phospho-IKK (Ser176/180) of IKK, I κ B α and p65 total protein and specific site phosphorylation, phospho-I κ B α (Ser32), and phospho-p65 (Ser536)).
Fig. 5 (b) can find out, IKK, the antibody p-IKK (Ser176/180) of I κ B α and p65 total protein and specific site phosphorylation, the expressing quantity of p-I κ B α (Ser32) and p-p65 (Ser536) declines all to some extent.
Illustrate that the application's chirality nanofiber can not only induce the downward of NF-kappa B correlation factor transcriptional level, and the downward of NF-kappa B related protein phosphorylation level can be induced.
Embodiment 5:Zn-Asp chirality nanofiber is on the impact of tumour cell autophagocytosis
1, biological electron microscope aspect
200 μ g/mL D/L-(Zn-Asp) chirality nanofibers are joined 10%FBS cell culture medium incubated cell 24 hours, and the parallel control group not adding chirality nanofiber in cell culture medium is set.Discard culture medium, the PBS buffer solution of cell precooling is washed twice, then digests with pancreatin, fixed by postdigestive cell sample glutaraldehyde, be then transferred in osmic acid solution and be fixed, the cell after fixing is through epoxy resin embedding.Embedded cell sample slicer is cut into the section that thickness is 80nm, then dyes with uranium acetate, and the section of having dyeed is observed under biological electron microscope.
As can be seen from Fig. 6 (b) Electron microscopic findings, there is in cell cavity shape duplicature spline structure.
2, protein expression aspect
200 μ g/mL D/L-(Zn-Asp) chirality nanofibers are joined 10%FBS cell culture medium incubated cell 3,6,12 or 24 hours, and the parallel control group not adding chirality nanofiber in cell culture medium is set.After process, discard culture medium, the PBS buffer solution of cell precooling is washed twice, then add appropriate RIPA cell pyrolysis liquid and carry out lysis.Carry out quantitatively, respectively getting the protein of 25 μ g, adding 2 × sample-loading buffer to each product of cell lysis by BCA method, run SDS-PAGE electrophoresis, then carry out western blot detection, detect LC3 antibody.
This antibody detects two kinds of protein form: LC3-I and LC3-II of LC3 simultaneously.
As can be seen from Fig. 6 (a) and 6 (b), after nanofiber process, the total amount of LC3 protein and the relative amount of LC3-II raise all to some extent.Illustrate the application's chirality nanofiber can inducing cell autophagy reaction.
The preparation of comparative example 1:Zn-Asp chirality nanofiber
The preparation method of Zn-Asp chirality nanofiber with embodiment 1, with the interactional specific experiment step of tumor correlated albumen matter with embodiment 2.
The Zn-Asp chirality nanofiber of preparation is in threadiness, and diameter is at about 100nm, and length is 100 μm.
Result: this chirality nanofiber is consistent with the combination of tumor correlated albumen matter and the kind of nanofiber of the present invention, but due to surface area reduction, finally cause the content of conjugated protein to decline.
The interaction of comparative example 2:Ca-Asp chirality nanofiber and tumor correlated albumen matter
The preparation method of Ca-Asp chirality nanofiber with embodiment 1, with the interactional specific experiment step of tumor correlated albumen matter with embodiment 2.
Compared with the protein combined with Zn-Asp nanofiber, this nanofiber only interacts with three kinds of protein such as BSA.
The interaction of comparative example 3:Zn-Cys chirality nanofiber and tumor correlated albumen matter
The preparation method of Zn-Cys chirality nanofiber with embodiment 1, with the interactional specific experiment step of tumor correlated albumen matter with embodiment 2.
The protein band that this nanofiber combines is almost consistent with the protein band that Zn-Asp nanofiber combines.
As can be seen from embodiment 1-5 and comparative example, Zn-Asp chirality nanofiber of the present invention is low to the suppression of cell viability in 1% blood serum medium, can in conjunction with HSP90, can in conjunction with multi-form gelatinase, reduce the content of extracellular gelatinase, larger impact is caused on the migration and invasion vigor of cell, and the downward of NF-kappa B correlation factor transcriptional level and NF-kappa B related protein phosphorylation level can be induced.
In sum, Zn-Asp chirality nanofiber of the present invention by affecting the function of extracellular HSP90, thus affects extracellular HSP90 associated signal paths, can be good at invasion and attack and the migratory activity of Tumor suppression, reaches the object for the treatment of tumour.
Applicant states, the present invention illustrates method detailed of the present invention by above-described embodiment, but the present invention is not limited to above-mentioned method detailed, does not namely mean that the present invention must rely on above-mentioned method detailed and could implement.Person of ordinary skill in the field should understand, any improvement in the present invention, to equivalence replacement and the interpolation of auxiliary element, the concrete way choice etc. of each raw material of product of the present invention, all drops within protection scope of the present invention and open scope.
Claims (8)
1. a chirality nanofiber, is characterized in that, described chirality nanofiber raw material comprises zinc ion and chiral amino acid,
Wherein, the diameter of described chirality nanofiber is 120-160nm.
2. chirality nanofiber according to claim 1, is characterized in that, described chiral amino acid is D/L-aspartic acid or D/L-cysteine, is preferably D/L-aspartic acid.
3. chirality nanofiber according to claim 1 and 2, is characterized in that, the diameter of described chirality nanofiber is 130-160nm;
Preferably, the length of described chirality nanofiber is 150-800 μm, is preferably 200-500 μm.
4. the chirality nanofiber according to any one of claim 1-3, is characterized in that, the synthetic method of described chirality nanofiber is self-assembly method.
5. prepare a preparation method for the chirality nanofiber according to any one of claim 1-4, it is characterized in that, comprise the following steps:
(1) chiral amino acid and zinc nitrate solution is prepared;
(2) by zinc nitrate solution titration chiral amino acid solution under the condition stirred, mixture reacts 7-18 days on the interface of water-absolute ethyl alcohol, then with 10mL absolute methanol washing 3-5 time, puts into vacuum drying chamber dry.
6. the chirality nanofiber according to any one of claim 1-4 is for affecting the purposes of extracellular HSP90 associated signal paths;
Preferably, described signal path is NF-kappa B.
7. the application of the chirality nanofiber according to any one of claim 1-4 in preparation treatment and prevention cancer drug.
8. application according to claim 7, it is characterized in that, described cancer is the combination of any one or at least two kinds in cancer of the stomach, liver cancer, the carcinoma of the rectum, colon cancer, ED-SCLC, prognosis of squamous cell lung cancer, adenocarcinoma of lung, bronchiolar adenocarcinoma, thyroid cancer, cervical carcinoma, oophoroma, prostate cancer, the cancer of the esophagus, lymphepithelioma, melanoma, breast cancer, duct carcinoma, osteosarcoma, basosquamous cell carcinoma, carcinoma of urinary bladder, neuroblastoma or glioblastoma.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510321191.6A CN104975376A (en) | 2015-06-12 | 2015-06-12 | Chiral nanometer fiber and its preparation method and use |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510321191.6A CN104975376A (en) | 2015-06-12 | 2015-06-12 | Chiral nanometer fiber and its preparation method and use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104975376A true CN104975376A (en) | 2015-10-14 |
Family
ID=54272325
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510321191.6A Pending CN104975376A (en) | 2015-06-12 | 2015-06-12 | Chiral nanometer fiber and its preparation method and use |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104975376A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111266598A (en) * | 2018-12-05 | 2020-06-12 | 同济大学 | Preparation method of chiral metal nano spiral fiber array |
| CN113912134A (en) * | 2021-10-11 | 2022-01-11 | 江南大学 | Chiral cobalt hydroxide nano particle and preparation method and application thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1210750A (en) * | 1997-09-08 | 1999-03-17 | 中国科学院成都有机化学研究所 | Chiral ligand exchanging and separating membrane and its preparing method |
| CN101641338A (en) * | 2006-09-11 | 2010-02-03 | 柯瑞斯公司 | Multi-functional small molecules as anti-proliferative agents |
| CN103387603A (en) * | 2012-05-08 | 2013-11-13 | 复旦大学 | Polypeptide related to RTN4B, and preparation and application thereof |
-
2015
- 2015-06-12 CN CN201510321191.6A patent/CN104975376A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1210750A (en) * | 1997-09-08 | 1999-03-17 | 中国科学院成都有机化学研究所 | Chiral ligand exchanging and separating membrane and its preparing method |
| CN101641338A (en) * | 2006-09-11 | 2010-02-03 | 柯瑞斯公司 | Multi-functional small molecules as anti-proliferative agents |
| CN103387603A (en) * | 2012-05-08 | 2013-11-13 | 复旦大学 | Polypeptide related to RTN4B, and preparation and application thereof |
Non-Patent Citations (2)
| Title |
|---|
| ERDAN CHEN等: ""Chiral Zinc Phenylalanine Nanofibers"", 《JOURNAL OF NANOSCIENCE AND NANOTECHNOLOGY》 * |
| 张海辉: ""手性纳米纤维的冠状蛋白和细胞学效应研究"", 《中国优秀硕士学位论文全文数据库 医药卫生科技辑》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111266598A (en) * | 2018-12-05 | 2020-06-12 | 同济大学 | Preparation method of chiral metal nano spiral fiber array |
| CN111266598B (en) * | 2018-12-05 | 2022-06-21 | 同济大学 | Preparation method of chiral metal nano spiral fiber array |
| CN113912134A (en) * | 2021-10-11 | 2022-01-11 | 江南大学 | Chiral cobalt hydroxide nano particle and preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Huang et al. | Development of a novel RNAi therapy: engineered miR-31 exosomes promoted the healing of diabetic wounds | |
| Li et al. | Anticancer effects of sweet potato protein on human colorectal cancer cells | |
| Cheng et al. | Biomimicking platelet–monocyte interactions as a novel targeting strategy for heart healing | |
| JP2021526548A (en) | Targeting M2-like tumor-related macrophages with melittin-based apotosy-promoting peptide peptides | |
| CN105879030A (en) | Synergistic drug compound for treating tumor and preparation method thereof | |
| Marsh et al. | The Gaboon viper, Bitis gabonica: hemorrhagic, metabolic, cardiovascular and clinical effects of the venom | |
| WO2021134512A1 (en) | New function and use of cryptoid crab antimicrobial peptide scyreprocin | |
| Hou et al. | OGA activated glycopeptide-based nano-activator to activate PKM2 tetramerization for switching catabolic pathways and sensitizing chemotherapy resistance | |
| CN104975376A (en) | Chiral nanometer fiber and its preparation method and use | |
| Aliev et al. | Free radical generators cause changes in endothelial and inducible nitric oxide synthases and endothelin-1 immunoreactivity in endothelial cells from hyperlipidemic rabbits | |
| Xu et al. | Effects of icariin and curcumol on autophagy, ferroptosis, and lipid metabolism based on miR‐7/m‐TOR/SREBP1 pathway on prostate cancer | |
| Xia et al. | Adenosine A2a receptor regulates autophagy flux and apoptosis to alleviate ischemia-reperfusion injury via the cAMP/PKA signaling pathway | |
| KR20160008425A (en) | Composition for improvement of liver function comprising exopolysaccharide derived from ceriporia lacerata culture broth extracts as an active ingredient | |
| JP2021505574A (en) | Tumor cell abnormal lipid metabolism inhibitors containing plant-derived cyclic peptides as active ingredients and their use | |
| Dixon | Excystment of metacercariae of Fasciola hepatica L. in vitro | |
| Peng et al. | Multi-omics analyses revealed key factors involved in fluorescent carbon-dots-regulated secondary metabolism in Tetrastigma hemsleyanum | |
| CN105504063A (en) | Defensin-albumin anti-tumor fusion protein and preparation and application thereof | |
| CN107137404B (en) | Application of neferine in preparation of medicine for preventing or treating acute respiratory distress syndrome | |
| Tang et al. | microRNA‐497 inhibition mitigates myocardial infarction via enhancing wingless/integrated signal pathway in bone marrow mesenchymal stem cells | |
| Assreuy et al. | Vascular effects of a sulfated polysaccharide from the red marine alga Solieria filiformis | |
| Subjeck et al. | Heat shock proteins and cancer therapy: the trail grows hotter! | |
| CN101456854A (en) | Medicine novel use of procyanidine oligomer and multimer | |
| JP5461082B2 (en) | A novel microorganism belonging to the genus Streptomyces, a novel compound produced by the microorganism, and a pharmaceutical comprising the compound as an active ingredient | |
| Pobe et al. | Prevention of human bladder tumor cell implantation in an in vitro assay | |
| CN105168199A (en) | Application of curcumenol in preparing drug for performing targeted inhibiting on tumor cell EZH2 protein |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20151014 |